E. Ohman J or Asset Management AB Has $877,000 Stock Holdings in Natera, Inc. $NTRA

E. Ohman J or Asset Management AB decreased its stake in Natera, Inc. (NASDAQ:NTRA) by 88.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 3,232 shares of the medical research company’s stock after selling 24,163 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Natera were worth $877,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Coatue Management LLC increased its holdings in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new stake in shares of Natera during the 4th quarter valued at $372,398,000. JPMorgan Chase & Co. grew its position in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in Natera by 39.0% during the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after acquiring an additional 673,315 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. The Goldman Sachs Group began coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price for the company. Morgan Stanley reissued an “overweight” rating and set a $355.00 price target on shares of Natera in a research note on Monday. Wolfe Research assumed coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. BTIG Research upped their price objective on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday. Finally, Citigroup raised their price objective on shares of Natera from $300.00 to $315.00 and gave the company a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $301.90.

Natera Stock Down 1.8%

NASDAQ NTRA opened at $312.72 on Wednesday. The company has a market capitalization of $45.08 billion, a price-to-earnings ratio of -229.94 and a beta of 1.51. Natera, Inc. has a twelve month low of $152.62 and a twelve month high of $326.03. The stock has a fifty day simple moving average of $258.02 and a 200 day simple moving average of $224.81.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.82% and a negative net margin of 7.11%.The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the business earned ($0.74) EPS. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. Research analysts expect that Natera, Inc. will post -1.5 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares in the company, valued at $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 181,045 shares of company stock valued at $41,330,968 over the last ninety days. Insiders own 5.05% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.